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β-Human chorionic gonadotropin (β-HCG) is an embryonic protein secreted by the syncytiotrophoblast of the placenta. The 
determination of the plasma β-HCG level is routinely used for the diagnosis and the follow-up of germ cell tumors. Some adeno-
carcinomas have been described as being rarely associated with β-HCG hypersecretion. We report a case of gastric signet-ring cell 
carcinoma with β-HCG hypersecretion and propose hypotheses to explain the pathogenesis of such hypersecretion.
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β-Human chorionic gonadotropin (β-HCG) 
is an embryonic protein secreted by the syncytiotro-
phoblast of the placenta. The determination of the 
plasma β-HCG level is routinely used for the diagnosis 
and the follow-up of germ-cell tumors. Some adeno-
carcinomas have been described as being rarely as-
sociated with β-HCG hypersecretion. Amongst these 
adenocarcinomas, gastric and pulmonary origin was 
the most frequent. Its incidence ranges from 10.9% 
to 16.7% and 12% to14%, respectively, in gastric ad-
enocarcinoma and lung cancer [1]. We report a case 
of gastric signet-ring cell carcinoma with β-HCG hy-
persecretion and we propose to analyze hypotheses 
to explain the pathogenesis of this hypersecretion.
ObSERVATION
A 52-year-old man was admitted for hematemesis 
with dysuria. Clinical examination showed an ascites. 
Oesogastroduodenal fibroscopy revealed an ec-
chymotic funditic gastropathy with bulbo-duodenitis. 
Histopathological study of gastric biopsy concluded 
to a signet-ring cell carcinoma of the fundial mucosa 
with non-atrophic and non-active chronic antro-fun-
gal gastritis (Fig. 1). Duodenal biopsy was normal. 
A thoraco-abdomino-pelvic computed tomography 
showed a thickening of the gastric wall with a regular 
thickening of the anterior wall of the bladder of 10 mm 
(Fig. 2) and multiple osteo-condensing lesions of the 
iliac bone, sacrum, dorsolumbar spine and sternum. 
Cystoscopy showed a budding lesion of the anterior 
wall of the bladder. The patient had an endoscopic 
resection of the bladder tumor. Histologically, there 
was an undifferentiated tumor cells infiltration with iso-
lated round-sized cells crushed with a cytoplasm. The 
nuclear pleomorphism was low and the tumor stroma 
was fibrous and abundant (Fig. 3). This proliferation 
extended to the muscularis. At immunohistochemical 
study, the tumor cells were positive for anti-keratin, 
ACE and HCG (Fig. 4). This study concluded to a blad-
der infiltration by signet-ring cell carcinoma of gastric 
origin. Testicular ultrasound was normal. β-HCG level 
was 458 mIU/ml. The patient had received palliative 
chemotherapy with EOX protocol (epirubicin, oxalipla-
tin, capecitabine) and biphosphonate. Control β-HCG 
level was 4 mIU/ml.
Fig. 1. Histological study of gastric biopsy. Infiltration of the 
fundic mucosa by tumor cells. Hematoxylin-eosin, × 400
Fig. 2. Pelvic CT: regular thickening of the anterior wall of the 
bladder
DISCUSSION
β-HCG is a glycoprotein hormone consisting of two 
subunits: α and β which are joined by noncovalent 
bonds. Since the α-subunit of HCG has a sequence 
homology similar to other pituitary hormones, includ-
ing luteinizing hormone, thyroid-stimulating hormone 
and follicle-stimulating hormone, the β-subunit 
of HCG is assayed. HCG is physiologically produced 
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by syncytiotrophoblasts of the placenta and in in-
creased amounts by germ cells tumors, particularly 
choriocarcinoma. β-HCG production have been pre-
viously described in oropharyngeal squamous cell 
carcinoma [1], urothelial carcinoma of bladder [2], 
clear cell renal cell carcinoma [3], leiomyosarcoma 
[4] and malignant phyllodes tumor of the breast [5]. 
Expression of serum β-HCG is not associated with any 
specific histological subtypes, although some authors 
have found that this phenomenon is more characteris-
tic of adenocarcinoma [3]. A rare subset of tumors with 
hyperexcretion of β-HCG has been identified in non-
trophoblastic cells, amongst gastric adenocarcinoma. 
The β-HCG-positive cells were located mainly in the 
antral mucosa and were generally restricted to a low 
portion of the pyloric and fundic glands [6] such in our 
case. The β-HCG-immunoreactive cells were found 
more often in advanced carcinomas that were histo-
logically poorly differentiated than in early carcinomas 
or in well-differentiated tumors [6]. To our knowledge, 
our case represents the second report of a gastric 
signet-ring cell carcinoma producing β-HCG. This 
patient had also multiple osteo-condensing lesions 
of the iliac bone, the sacrum and the dorsolumbar 
spine. By reviewing the literature, bone metastases 
are five times more frequent in β-HCG secreting gastric 
adenocarcinoma than in nonsecreting tumors [7, 8].
β-HCG production is correlated with a poor prog-
nosis in a multivariate analysis of 290 gastric adeno-
carcinoma patients [9]. Tomita and Kuwajima [10] re-
ported that patients with gastric cancer and high levels 
of HCG in the serum or a high density of HCG-positive 
cells in the tumor tissue had a poor prognosis. Also, 
Ito and Tahara [11] who found β-HCG-positive tumor 
cells in 8.2% of the advanced cancer cases reported 
that gastric cancers with HCG immunoreactivity tended 
toward a poorer prognosis.
The mechanism of β-HCG secretion is poorly 
understood. It can be explained by a trophoblastic 
metaplasia within the carcinomatous tissue. Other 
hypotheses have been proposed to explain the origin 
of β-HCG-producing cells and include the following: 
displaced totipotential or gonadal cells (extragonadal 
choriocarcinomas); metastasis from an intrauterine 
or gonadal lesion and the presence of β-HCG-specific 
mRNA and the possibility of reactivation of β-HCG 
gene transcription in the malignant transformed cells, 
leading to ectopic β-HCG protein expression [12–14]. 
To date, few published reports have attempted to ad-
dress this issue by exploring ectopic β-HCG produc-
tion at the molecular level. Besides their important 
biological role in promoting progesterone production 
and angiogenesis in the uterine vasculature during 
pregnancy, free β-subunit and hyperglycosylated 
HCG were recently found to play a major role in the 
tumorigenesis of nontrophoblastic tumors. They acted 
as an autocrine antiapoptotic and angiogenic growth 
factor that inhibits the TGF- β apoptosis signaling path-
way, resulting in cancer cell growth [15, 16]. This may 
also explain the chemoresistance and aggressiveness 
of β-HCG secreting tumors.
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